First National Bank of Omaha grew its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 40.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,591 shares of the biopharmaceutical company’s stock after buying an additional 1,035 shares during the period. First National Bank of Omaha’s holdings in Gilead Sciences were worth $257,000 as of its most recent SEC filing.
A number of other large investors have also recently added to or reduced their stakes in GILD. FMR LLC raised its stake in Gilead Sciences by 1.1% during the 2nd quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock valued at $1,630,581,000 after acquiring an additional 258,005 shares in the last quarter. Macquarie Group Ltd. raised its stake in Gilead Sciences by 26.6% during the 3rd quarter. Macquarie Group Ltd. now owns 479,332 shares of the biopharmaceutical company’s stock valued at $38,836,000 after acquiring an additional 100,741 shares in the last quarter. Vanguard Group Inc. raised its stake in Gilead Sciences by 2.4% during the 2nd quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock valued at $6,571,355,000 after acquiring an additional 2,148,697 shares in the last quarter. Northern Trust Corp raised its stake in Gilead Sciences by 0.7% during the 2nd quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock valued at $1,162,949,000 after acquiring an additional 116,780 shares in the last quarter. Finally, Toronto Dominion Bank raised its stake in Gilead Sciences by 19.0% during the 2nd quarter. Toronto Dominion Bank now owns 472,577 shares of the biopharmaceutical company’s stock valued at $33,445,000 after acquiring an additional 75,364 shares in the last quarter. 77.83% of the stock is currently owned by institutional investors.
In other Gilead Sciences news, Director John Francis Cogan sold 5,833 shares of the business’s stock in a transaction dated Monday, March 12th. The stock was sold at an average price of $80.93, for a total value of $472,064.69. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP James R. Meyers sold 100,000 shares of the business’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $80.24, for a total value of $8,024,000.00. Following the completion of the sale, the executive vice president now directly owns 102,715 shares of the company’s stock, valued at approximately $8,241,851.60. The disclosure for this sale can be found here. In the last three months, insiders have sold 430,268 shares of company stock valued at $34,074,395. Insiders own 1.30% of the company’s stock.
Several analysts have weighed in on GILD shares. Maxim Group raised Gilead Sciences from a “hold” rating to a “buy” rating and lifted their target price for the company from $73.67 to $94.00 in a research note on Thursday, November 30th. Credit Suisse Group reiterated a “buy” rating and set a $82.00 price target on shares of Gilead Sciences in a research report on Thursday, December 7th. BidaskClub upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Thursday, December 14th. Oppenheimer reiterated a “hold” rating on shares of Gilead Sciences in a research report on Thursday, December 21st. Finally, Zacks Investment Research cut Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, December 27th. One analyst has rated the stock with a sell rating, ten have given a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $88.61.
Gilead Sciences stock opened at $79.74 on Monday. Gilead Sciences, Inc. has a twelve month low of $63.76 and a twelve month high of $89.54. The company has a current ratio of 2.74, a quick ratio of 2.67 and a debt-to-equity ratio of 1.53. The firm has a market capitalization of $104,456.84, a price-to-earnings ratio of 22.91, a PEG ratio of -1.83 and a beta of 1.24.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.67 by $0.11. The firm had revenue of $5.95 billion during the quarter, compared to analysts’ expectations of $5.71 billion. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The business’s revenue for the quarter was down 18.7% on a year-over-year basis. During the same quarter last year, the firm earned $2.70 earnings per share. analysts expect that Gilead Sciences, Inc. will post 6.21 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 29th. Investors of record on Friday, March 16th will be given a dividend of $0.57 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date is Thursday, March 15th. This represents a $2.28 dividend on an annualized basis and a yield of 2.86%. Gilead Sciences’s dividend payout ratio (DPR) is presently 65.52%.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.